Silexion Therapeutics (SLXN)
NASDAQ:SLXN
Want to see SLXN full AI Analyst Report?
Top Page
Silexion Therapeutics
(NASDAQ:SLXN)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.52
▼(-75.57% Downside)
Action:Reiterated
Date:05/21/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and heavy cash burn implying continued funding needs) and bearish technicals (price below all key moving averages with negative MACD). Corporate events provide some offset via tangible clinical/manufacturing/regulatory progress, while valuation signals are not robust given the loss-making profile and lack of dividend data.
Positive Factors
Clinical trial advancement
Regulatory clearance to start a Phase 2/3 trial is a durable de-risking milestone: it moves SIL204 from preclinical to pivotal clinical testing, enables generation of meaningful efficacy/safety data, improves partnership and licensing prospects, and validates the development pathway across jurisdictions.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow at material levels creates recurring financing need. Over the medium term this constrains R&D pacing, forces fundraising during development, raises dilution risk, and limits strategic optionality unless cash runway is extended by fresh capital or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical trial advancement
Regulatory clearance to start a Phase 2/3 trial is a durable de-risking milestone: it moves SIL204 from preclinical to pivotal clinical testing, enables generation of meaningful efficacy/safety data, improves partnership and licensing prospects, and validates the development pathway across jurisdictions.
Read all positive factors
Silexion Therapeutics (SLXN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.09M
Dividend YieldN/A
Average Volume (3M)50.14K
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue GrowthN/A
EPS Growth96.81%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)6.64
Shares Outstanding4,189,954
10 Day Avg. Volume60,134
30 Day Avg. Volume50,136
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit188.50
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$6.00Price Target Upside183.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.25
Revenue Forecast (FY)N/A
Silexion Therapeutics Business Overview & Revenue Model
Company Description
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its propri...
How the Company Makes Money
As a clinical-stage biotechnology company, Silexion Therapeutics has not publicly disclosed a recurring product-revenue business (e.g., sales of approved drugs) as a primary source of income. Accordingly, its funding is generally expected to come ...
Silexion Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.90M | -11.88M | -16.48M | -4.64M | -3.80M | -755.00K |
| Net Income | -12.91M | -11.91M | -16.44M | -4.94M | -3.21M | -755.22K |
Balance Sheet | ||||||
| Total Assets | 4.60M | 7.21M | 2.86M | 5.26M | 9.33M | 115.41M |
| Cash, Cash Equivalents and Short-Term Investments | 2.41M | 5.99M | 1.19M | 4.59M | 8.26M | 38.94K |
| Total Debt | 436.00K | 468.00K | 4.49M | 171.00K | 271.00K | 0.00 |
| Total Liabilities | 4.31M | 4.61M | 6.85M | 17.31M | 16.41M | 508.92K |
| Stockholders Equity | 291.00K | 2.60M | -3.99M | -15.48M | -10.66M | 114.91M |
Cash Flow | ||||||
| Free Cash Flow | -12.02M | -10.83M | -8.42M | -4.54M | -3.38M | -1.41M |
| Operating Cash Flow | -12.01M | -10.82M | -8.40M | -4.53M | -3.33M | -1.41M |
| Investing Cash Flow | -8.00K | -14.00K | -22.00K | 573.00K | -524.00K | 0.00 |
| Financing Cash Flow | 8.29M | 15.64M | 5.10M | 522.00K | 2.75M | 116.40M |
Silexion Therapeutics Technical Analysis
Negative
2.12
Price Trends
0.93
Negative
1.39
Negative
2.75
Negative
Market Momentum
-0.15
Negative
40.81
Neutral
62.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLXN, the sentiment is Negative. The current price of 2.12 is above the 20-day moving average (MA) of 0.53, above the 50-day MA of 0.93, and below the 200-day MA of 2.75, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 40.81 is Neutral, neither overbought nor oversold. The STOCH value of 62.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLXN.
Silexion Therapeutics Risk Analysis
Silexion Therapeutics disclosed 56 risk factors in its most recent earnings report. Silexion Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Silexion Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $5.93M | -0.11 | -684.86% | ― | ― | 95.40% | |
46 Neutral | $2.09M | -0.38 | -529.06% | ― | ― | 96.81% | |
43 Neutral | $4.79M | -1.28 | -418.83% | ― | ― | 97.67% | |
42 Neutral | $20.45M | -0.25 | 0.02% | ― | ― | -101.45% | |
40 Underperform | $1.33M | -1.65 | 1211.14% | ― | -74.05% | 73.08% |
* Healthcare Sector Average
SLXN
Silexion Therapeutics
0.50
-14.65
-96.70%
MBIO
Mustang Bio
0.63
-0.66
-51.01%
LYRA
Lyra Therapeutics
0.75
-3.64
-82.92%
RNAZ
TransCode Therapeutics
6.24
-0.63
-9.17%
AEON
AEON Biopharma
0.78
0.17
27.38%
Silexion Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Silexion Therapeutics Announces Warrant Inducement Financing Agreement
Positive
May 15, 2026
On May 15, 2026, Silexion Therapeutics entered into an inducement agreement with holders of 1,995,092 existing warrants, who agreed to exercise those warrants for cash at a reduced price of $0.50 per share in exchange for new Series C and Series D...
Business Operations and StrategyProduct-Related Announcements
Silexion Announces Positive Preclinical Data for SIL204 Therapy
Positive
May 14, 2026
On May 14, 2026, Silexion Therapeutics reported positive preliminary results from an ongoing translational immuno-oncology preclinical study of its lead RNAi candidate SIL204 in human KRAS-mutated pancreatic cancer cells. The study showed a statis...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Silexion Advances SIL204 With Manufacturing and Trial Approval
Positive
May 13, 2026
On May 13, 2026, Silexion Therapeutics announced it has begun Good Manufacturing Practice clinical batch manufacturing of SIL204, its next-generation siRNA therapy targeting mutated KRAS in locally advanced pancreatic cancer, with Catalent at the ...
Business Operations and StrategyDelistings and Listing ChangesShareholder MeetingsStock Split
Silexion Therapeutics Shareholders Approve Capital Increase, Reverse Split
Positive
May 5, 2026
At an extraordinary general meeting originally held on April 28, 2026, and reconvened on May 5, 2026, Silexion Therapeutics shareholders approved an amendment to increase the company’s authorized share capital from 9,000,000 to 59,000,000 or...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Silexion advances SIL204 to EU Phase 2/3 pancreatic trial
Positive
Apr 28, 2026
On April 28, 2026, Silexion Therapeutics announced it had successfully submitted a Clinical Trial Application to Germany’s BfArM via the EU Clinical Trials Information System for a planned Phase 2/3 trial of its lead siRNA candidate, SIL204,...
Executive/Board Changes
Silexion Therapeutics Announces Immediate Board Membership Change
Neutral
Mar 25, 2026
On March 25, 2026, Silexion Therapeutics Corp. announced that its Board of Directors unanimously removed Ilan Levin from his position as a board member, effective immediately. The action was taken in writing by all other directors under the compan...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Silexion gains approval for SIL204 pancreatic cancer trial
Positive
Mar 24, 2026
On March 24, 2026, Silexion Therapeutics announced that the Israeli Ministry of Health had approved initiation of a Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, following strong anti-tumor activity in multiple preclini...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Silexion Shareholders Reject Capital Increase and Plan Amendments
Negative
Mar 23, 2026
On March 23, 2026, Silexion Therapeutics reconvened an extraordinary general meeting originally held on March 16, 2026, after the first session was adjourned for lack of quorum. Under its articles of association, the shareholders present after a 3...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.